Being a CYP2D6 poor metabolizer means your body processes certain drugs through this enzyme far more slowly than most people, which can raise blood levels of drugs that CYP2D6 normally clears and leave prodrugs like codeine unconverted into their active form. The practical result splits in two directions depending on the drug: higher exposure and side-effect risk for some medications, or little to no therapeutic effect for others. The sections below explain how genotype determines this status, which drugs are affected, and what to do with the result.
TL;DR:
- Approximately 7% of European-ancestry individuals are likely poor CYP2D6 metabolizers, while prevalence varies across other populations due to different allele distributions.
- Active drugs such as metoprolol and amitriptyline tend to accumulate in poor metabolizers, increasing side-effect risks, whereas prodrugs like codeine may produce little to no effect.
- Strong inhibitors like paroxetine or fluoxetine can temporarily shift normal metabolizers to a poor metabolizer state, affecting drug processing regardless of genetic status.
- CYP2D6 testing results can be limited by incomplete allele panels and variations in interpretation, making genotype-to-phenotype translation critical for clinical decision-making.
- Management strategies for poor metabolizers include avoiding certain prodrugs, adjusting doses of active drugs, or choosing alternatives, often coupled with close monitoring or blood level testing.
Table of Contents
- How CYP2D6 genetics determine your metabolizer status
- How common is the poor metabolizer phenotype
- Which drugs rely on CYP2D6 and what that means for you
- Why your other medications can change how your genotype behaves
- How to read your CYP2D6 lab report
- What clinicians typically do with a poor metabolizer result
- How living pharmacogenomic reporting keeps CYP2D6 guidance current
- Why sharing your CYP2D6 result matters more than having it
- Bringing CYP2D6 reporting into your lab's workflow
- FAQ
- Sources
How CYP2D6 genetics determine your metabolizer status
CYP2D6 is one of the liver's main drug-processing enzymes, part of the cytochrome P450 family that breaks down roughly a fifth of commonly prescribed medications, according to a review of CYP2D6 phenoconversion. Unlike many other P450 enzymes, CYP2D6 activity is shaped almost entirely by genetics rather than diet or lifestyle, which is why a single genetic test can predict so much about how you will respond to a given drug.
The gene comes in dozens of documented variants, cataloged under a naming system called star alleles (written as, for example, *1, *4, or *10). Each star allele carries its own functional status: normal function, reduced function, no function, or increased function through gene duplication. Someone who inherits two no-function alleles, such as *4/*4, produces an enzyme that barely works at all.
To translate that genetic detail into something clinically usable, laboratories calculate an activity score. Each allele gets a numeric value based on how much enzyme function it retains, and the two allele scores are added together to produce a diplotype-level score, a method detailed in CPIC's genotype-to-phenotype consensus table. The resulting number maps onto a phenotype category:
- Activity score of 0: poor metabolizer (PM), as defined in NCBI's pharmacogenomics overview, typically from two no-function alleles.
- Activity score around 0.5: intermediate metabolizer (IM), often one no-function and one reduced-function allele.
- Activity score of 1 to 2: normal metabolizer (NM), sometimes still labeled "extensive metabolizer" on older reports.
- Activity score above 2: ultrarapid metabolizer (UM), usually from gene duplication that multiplies enzyme output.
Labs do not always print the term "activity score." Some reports list only the diplotype and a phenotype label, others show the score explicitly, and a few use older terminology inherited from earlier guideline versions. Whatever the format, the activity score is the standardized calculation behind the label, which matters because it is also the number clinicians adjust later when accounting for interacting medications.
How common is the poor metabolizer phenotype
Poor metabolizer status is not rare, but how common it is depends heavily on ancestry, because the no-function alleles behind it are not evenly distributed across populations. A review of CYP2D6 molecular genetics notes prevalence around 7% in some populations of European descent, with different frequencies reported in East Asian and African populations due to distinct allele patterns.
An estimated 7% of some European-ancestry populations carry the poor metabolizer phenotype, according to CYP2D6 clinical relevance research, a frequency high enough that most prescribers encounter poor metabolizers regularly without necessarily knowing it.
The variation comes down to which no-function and reduced-function alleles are common in a given population's gene pool. East Asian populations tend to carry a higher frequency of reduced-function alleles like *10, which often produces intermediate rather than poor metabolizer status, while African and African American populations show their own distinct allele distribution, including variants like *17 and *29.
None of this means ancestry can substitute for testing. Population frequencies describe groups, not individuals, and plenty of people fall outside their ancestry group's typical pattern. If a prescribing decision depends on CYP2D6 status, a lab-confirmed diplotype and activity score remain the only way to know where a specific patient actually falls.
Which drugs rely on CYP2D6 and what that means for you
CYP2D6 processes a disproportionately large share of widely prescribed drugs relative to its modest size among P450 enzymes, and that reach spans several major drug classes you have likely encountered.
- Opioids: codeine and tramadol require CYP2D6 to convert into their active, pain-relieving forms.
- Antidepressants: many tricyclics and several SSRIs, including amitriptyline and paroxetine, are CYP2D6 substrates.
- ADHD medication: atomoxetine is metabolized almost entirely through this pathway.
- Beta-blockers: metoprolol clearance depends heavily on CYP2D6 activity.
- Antiemetics and other substrates: several nausea medications and the active metabolite pathway for tamoxifen also run through CYP2D6.
The clinical consequence depends on whether the drug is active on its own or needs CYP2D6 to activate it. For active drugs like metoprolol, amitriptyline, or atomoxetine, poor metabolizer status means the drug clears more slowly, blood levels climb higher than intended, and side effects become more likely at standard doses. For prodrugs like codeine and, to a degree, tramadol, poor metabolizer status means the opposite problem: without enough CYP2D6 activity to convert the drug into its active form, pain relief may be minimal or absent even at full doses.
| Drug or class | CYP2D6 role | Poor metabolizer concern |
|---|---|---|
| Codeine | Prodrug, needs activation | Little to no pain relief |
| Tramadol | Partial prodrug | Reduced analgesic effect |
| Atomoxetine | Active drug, cleared by CYP2D6 | Higher exposure, more side effects |
| Metoprolol | Active drug, cleared by CYP2D6 | Slower clearance, higher blood levels |
| Amitriptyline | Active drug, cleared by CYP2D6 | Elevated levels, higher toxicity risk |
Several SSRIs, notably paroxetine and fluoxetine, are not just substrates but also potent inhibitors of the same enzyme, which complicates the picture further when they are taken alongside other CYP2D6-dependent drugs. What a poor metabolizer result actually calls for, whether that means a dose adjustment, a different drug entirely, or simply closer monitoring, depends on the specific medication, the dose involved, and the rest of the clinical picture, which is why genotype results are meant to inform a prescriber's decision rather than replace it.
Why your other medications can change how your genotype behaves
Genotype tells only part of the story, because a process called phenoconversion can make a genetically normal metabolizer behave like a poor metabolizer, at least temporarily. Phenoconversion happens when a drug you are currently taking inhibits the CYP2D6 enzyme itself, regardless of what your DNA says it should be capable of doing. This dynamic is described in detail in research on CYP2D6 phenoconversion.
Strong or moderate CYP2D6 inhibitors can put a substantial proportion of patients on CYP2D6 substrates at risk of phenoconversion, according to phenoconversion research, a range wide enough to make medication review a routine part of interpreting any CYP2D6 result rather than an afterthought.
The FDA's drug interaction table classifies CYP2D6 inhibitors by strength, which matters because the degree of inhibition determines how much the apparent phenotype shifts:
- Strong inhibitors include paroxetine, fluoxetine, and bupropion, each capable of shutting down most CYP2D6 activity regardless of genotype.
- Moderate inhibitors include duloxetine and sertraline, which reduce activity substantially without eliminating it entirely.
- Quinidine, though rarely prescribed for its CYP2D6 effect today, remains one of the strongest known inhibitors and a reference point in pharmacology literature.
Clinical tutorials describe a practical way to account for this: when a strong inhibitor is on board, the activity score contribution from that pathway is effectively treated as zero, and with a moderate inhibitor, it is often cut roughly in half, an approach outlined in a tutorial on integrating phenoconversion into practice. A genetically normal metabolizer taking paroxetine daily may, in practical terms, process a CYP2D6 substrate about as poorly as someone who inherited two no-function alleles.
If you are reviewing your own CYP2D6 result, bring your complete medication list, including over-the-counter drugs and supplements, to the conversation with your clinician or pharmacist. Ask directly whether anything you are taking could be altering how your genotype actually behaves, and never stop or adjust a medication on your own based on a genetic report without guidance from the prescriber who manages it.
How to read your CYP2D6 lab report
A typical pharmacogenomic lab report for CYP2D6 includes several distinct pieces of information, and knowing what each one means makes the result far less intimidating.
- Star allele diplotype: the two specific CYP2D6 variants you carry, written as something like *4/*41.
- Calculated activity score: the numeric sum of both alleles' function, typically ranging from 0 to above 2.
- Predicted phenotype label: poor, intermediate, normal, or ultrarapid metabolizer, derived directly from the activity score.
- Drug-specific clinical guidance: notes or recommendations tied to specific medications you currently take or might be prescribed.
A diplotype of *4/*4, where both alleles carry no function, produces an activity score of 0 and a poor metabolizer label. A diplotype like *1/*4, pairing one fully functional allele with one no-function allele, produces an activity score around 1, generally read as normal metabolizer. A *1/*1x2 diplotype, reflecting gene duplication on one chromosome, can push the score above 2 and into ultrarapid territory. These are conceptual examples; the actual phenotype table used by laboratories, documented in CPIC's consensus guidance, covers far more allele combinations than any short list can capture.
Reports have limits worth knowing about. Some labs do not test for every rare allele, copy-number variation can be missed by certain testing methods, and a handful of results come back ambiguous when an allele's functional status is still debated in the scientific literature. Allele frequencies also differ by ancestry, so a panel designed with one population in mind may be less complete for another.
Pro Tip: If your report lists a diplotype you don't recognize or a phenotype that seems inconsistent with how a medication has worked for you in the past, ask your clinician whether a pharmacist or clinical pharmacogenomics specialist should review it.
When genotype results seem inconsistent with a patient's drug response, some clinicians order therapeutic drug monitoring, a blood test measuring the actual concentration of a drug or its metabolite, to confirm whether the predicted effect is showing up in practice.
What clinicians typically do with a poor metabolizer result
A confirmed CYP2D6 poor metabolizer result rarely triggers a single universal response. Instead, it shapes a set of drug-specific decisions that depend on whether the medication in question is a prodrug, an active drug cleared by CYP2D6, or something with a narrow therapeutic window where small exposure changes matter more.
- Avoiding codeine and certain prodrugs: since poor metabolizers cannot adequately activate these drugs, prescribers commonly choose a different analgesic entirely.
- Reducing doses of active-drug substrates: medications like metoprolol or amitriptyline may be started at a lower dose or titrated more cautiously.
- Choosing an alternative drug outside the CYP2D6 pathway: when available, this sidesteps the genotype issue altogether.
- Adding monitoring: closer follow-up or blood level checks when a dose reduction alone does not fully resolve the uncertainty.
| Scenario | Typical consideration |
|---|---|
| Codeine for pain | Avoid, since activation to morphine is impaired |
| Atomoxetine for ADHD | Consider dose reduction given sharply higher exposure |
| Metoprolol for hypertension | Dose caution or alternative beta-blocker |
| Tricyclic antidepressants | Lower starting dose with monitoring |
Modeling work on CYP2D6 drug interactions found that atomoxetine exposure can rise roughly tenfold in poor metabolizers, and that some combined drug-and-gene interaction scenarios call for dose reductions down to a small fraction of the standard amount, according to research on CYP2D6 drug-drug-gene interactions. That scale of change explains why genotype-informed dosing guidance exists for specific drugs rather than as a blanket rule.
Therapeutic drug monitoring plays a particularly useful role for drugs where plasma concentration correlates closely with either effect or toxicity, a point emphasized in KNMP's CYP2D6 background guidance. Rather than relying on genotype alone, a blood level check can confirm whether a predicted effect is actually occurring in that particular patient.
None of these decisions happen in isolation from the broader clinical picture, including kidney and liver function, other diagnoses, and patient preference. Documenting the genotype result and the medications it affects in the electronic health record, where the next prescriber can see it, is one of the simplest ways to make sure a one-time test keeps influencing care long after the original appointment.
How living pharmacogenomic reporting keeps CYP2D6 guidance current
A genotype result is static, but the guidance around it is not. CPIC and DPWG periodically revise genotype-to-phenotype translation rules, the FDA updates its inhibitor classifications as new interaction data emerges, and newly characterized alleles occasionally reshape how an existing diplotype should be interpreted. A report generated once and never revisited can quietly go out of date.
This is a structural problem that some reporting platforms aim to solve for laboratories. Some platforms fuse genotype data, medication history, and clinical evidence from multiple sources into a single physician-reviewed report, so a diplotype arrives already translated into an activity score, predicted phenotype, and drug-specific guidance rather than raw genetic notation a patient or prescriber has to decode manually.
Because phenoconversion depends on a patient's current medication list, not just their genes, medication intelligence simulations can evaluate how inhibitors on that list could shift an apparent phenotype, surfacing interaction risks before they become prescribing errors. Living reanalysis monitors reports against evolving guidelines and allele interpretations, flagging stored results for update when the clinical consensus behind them changes, instead of leaving reports frozen at the moment they were first issued.
For laboratories deploying this kind of reporting, White-Label PGx Reporting integrates with EHR systems through HL7/FHIR standards, keeping medical-director review and audit trails intact throughout.
Why sharing your CYP2D6 result matters more than having it
The most useful pharmacogenomic report is the one your prescriber actually sees and factors into a decision. I have come to think of a CYP2D6 result less as a diagnosis and more as a piece of context that only becomes valuable once it reaches the person writing the prescription.
A short checklist makes that handoff easier:
- Bring the actual report, not just a verbal summary, to every relevant appointment.
- Provide your complete medication list, including anything over the counter, since phenoconversion depends on it.
- Ask specific questions, such as whether a planned prescription is a known CYP2D6 substrate and what alternative exists if so.
Pharmacogenomics works best as a conversation between your genetics, your current medications, and your clinician's judgment, not as a standalone verdict, embodying the principles of personalized medicine and integrated data to improve clinical decisions.
— Tarek
Bringing CYP2D6 reporting into your lab's workflow
Clinical and reference laboratories that want to offer CYP2D6 and broader pharmacogenomic testing face a real operational challenge: turning raw genotype calls into reports a prescriber can trust and act on quickly, without building that infrastructure from scratch.
Some white-label infrastructures enable a lab to launch its own branded PGx reporting service in days rather than months, with evidence fusion, medication intelligence simulation, and living reanalysis built into the pipeline. Hospital systems and precision medicine programs can use such platforms to generate reports faster while maintaining medical-director review and regulatory compliance.
If your lab is evaluating how to operationalize CYP2D6 and other pharmacogenomic results for your clinicians, our White-Label PGx Reporting page outlines the Pilot, Standard, Scale, and Enterprise paths available, and our services overview covers Discovery & Strategy, System Design, and Deployment & Integration for teams ready to scope a project.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
What drugs should a CYP2D6 poor metabolizer avoid?
Poor metabolizers are generally advised to avoid codeine, since the enzyme needed to activate it into its pain-relieving form is largely absent. Other drugs, including certain tricyclic antidepressants, metoprolol, and atomoxetine, are not necessarily avoided outright but often require dose adjustment or closer monitoring under a clinician's guidance.
What does it mean if you are a poor metabolizer of CYP2D6?
It means your CYP2D6 enzyme activity score is 0, usually from inheriting two no-function gene variants, so the enzyme barely functions. For active drugs cleared through this pathway, that raises blood levels and side-effect risk, while for prodrugs like codeine, it can mean the drug never gets converted into its active form.
How do I know if I am a poor metabolizer?
The only reliable way is a pharmacogenomic test that reports your CYP2D6 diplotype and calculated activity score. Ancestry can hint at population-level likelihood, but it cannot substitute for an individual lab result.
What drugs are broken down by CYP2D6?
CYP2D6 processes roughly a fifth of commonly used medications, including codeine, tramadol, atomoxetine, metoprolol, several tricyclic antidepressants, and some SSRIs, according to research on CYP2D6 phenoconversion. It also contributes to the metabolic pathway for tamoxifen.
Sources
The clinical claims in this article draw on CPIC genotype-to-phenotype consensus guidance, FDA inhibitor classifications, and peer-reviewed research on phenoconversion and drug-gene interactions. Clinicians and curious readers looking to go deeper should start with the primary sources linked throughout the body above, including the CPIC translation table, the FDA substrate and inhibitor table, and the peer-reviewed phenoconversion and drug-drug-gene interaction studies cited in the relevant sections.